199 related articles for article (PubMed ID: 10763825)
1. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.
Voss J; Posern G; Hannemann JR; Wiedemann LM; Turhan AG; Poirel H; Bernard OA; Adermann K; Kardinal C; Feller SM
Oncogene; 2000 Mar; 19(13):1684-90. PubMed ID: 10763825
[TBL] [Abstract][Full Text] [Related]
2. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
3. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
5. The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.
Pecquet C; Nyga R; Penard-Lacronique V; Smithgall TE; Murakami H; Régnier A; Lassoued K; Gouilleux F
Oncogene; 2007 Mar; 26(11):1577-85. PubMed ID: 16953222
[TBL] [Abstract][Full Text] [Related]
6. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
7. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
de Jong R; van Wijk A; Heisterkamp N; Groffen J
Oncogene; 1998 Nov; 17(21):2805-10. PubMed ID: 9840945
[TBL] [Abstract][Full Text] [Related]
8. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
9. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
10. The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins.
Oehrl W; Kardinal C; Ruf S; Adermann K; Groffen J; Feng GS; Blenis J; Tan TH; Feller SM
Oncogene; 1998 Oct; 17(15):1893-901. PubMed ID: 9788432
[TBL] [Abstract][Full Text] [Related]
11. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion.
Jin A; Kurosu T; Tsuji K; Mizuchi D; Arai A; Fujita H; Hattori M; Minato N; Miura O
Oncogene; 2006 Jul; 25(31):4332-40. PubMed ID: 16518411
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
14. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
Jung JH; Pendergast AM; Zipfel PA; Traugh JA
Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
[TBL] [Abstract][Full Text] [Related]
16. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
[TBL] [Abstract][Full Text] [Related]
18. Adaptor proteins CRK and CRKL associate with the serine/threonine protein kinase GCKR promoting GCKR and SAPK activation.
Shi CS; Tuscano J; Kehrl JH
Blood; 2000 Feb; 95(3):776-82. PubMed ID: 10648385
[TBL] [Abstract][Full Text] [Related]
19. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
20. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes.
Genot E; Reif K; Beach S; Kramer I; Cantrell D
Oncogene; 1998 Oct; 17(13):1731-8. PubMed ID: 9796702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
